OnKure, Inc. Raises $55 Million Series B Financing

Mar 04, 2021•over 4 years ago

Amount Raised

$55 Million

Round Type

series b

Boulder

Description

OnKure, Inc., a privately-held biopharmaceutical company developing best-in-class, targeted oncology therapeutics, today announced that it has raised $55 million in a Series B financing. Proceeds will be used to advance the Company’s next generation histone deacetylase (HDAC) inhibitors further into clinical development and fund a growing pipeline of earlier stage molecules.

Company Information

Company

On Kure

Location

Boulder, Colorado, United States

About

OnKure, Inc. is a biopharmaceutical company focused on the discovery and development of targeted small molecule drugs to improve the outcomes of patients afflicted with cancer. OnKure’s drug candidates aim to treat patients through restoration of the epigenetic landscape, delaying resistance to other targeted therapies and exploiting synthetic lethalities. OnKure’s most advanced candidate, OKI-179, a potent and selective Class I HDAC inhibitor, is moving into Phase 2 studies in targeted populations. For more information about OnKure, please visit www.onkuretherapeutics.com.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

OnKure, Inc. Raises $55 Million Series B Financing

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information